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Evaluation of Organogel Nanoparticles as Drug Delivery System for Lipophilic 
Compounds 
Baptiste Martin,1 Fabien Brouillet,2 Sophie Franceschi,1 and Emile Perez1 ,3 
Abstmct. The purpose of the study was to evaluate organogel nanoparticles as a drug 
delivery system by investigating their stability, according to the formulation strategy, and 
their release profile. The gelled nanoparticles were prepared by hot emulsification (above the 
gelation temperature) of an organogel in water, and cooling at room temperature. In the first 
step, we used DLS and DSC to select the most suitable formulations by optimizing the 
proportion of ingredients (HSA, PVA, castor oil) to obtain particles of the smallest size and 
greatest stability. Then, two lipophilic drug models, indomethacin and ketoconazole were 
entrapped in the nanoparticles made of castor oil gelled by 12 hydroxystearic acid. Thermal 
studies (DSC) confirmed that there was no significant alteration of gelling due to the 
entrapped drugs, even at 3% whv. Very stable dispersions were obtained (>3 months), with 
gelled oil nanoparticles presenting a mean diameter between 250 and 300 nm. High 
encapsulation efficiency (>98%) was measured for indomethacin and ketoconazole. The 
release profile determined by in vitro dialysis showed an immediate release of the drug from 
the organogel nanoparticles, due to rapid diffusion. The study demonstrates the interest of 
these gelled oil nanoparticles for the encapsulation and the delivery of lipophilic active 
compounds. 
KEYWORDS: Drug delivery; Indomethacin; Ketoconazole; Organogel nanoparticles; 12 hydroxys tearic 
acid 
INTRODUCTION 
Interest in the use of colloidal lipid dispersions as drug 
carriers for poorly water soluble drug5 is rising. Systems 
including a lipid matrix are particularly under study as they 
allow a higher drug loading of lipophilic drugs (1, 2]. These 
lipid core drug carriers can be composed of liquid lipids, e.g., 
nanoemulsions, solid lipids, e.g., solid lipid nanoparticles 
(SLN), or even a mixture of both, e.g., nanostructured lipid 
carriers (NLC) (3]. Many examples in the literature illustrate 
the potential of these lipid nanoparticles for drug delivery, in 
particular for oral and topical routes (4 6]. However, their 
development can be limited by drug encapsulation issues. 
Higher drug contents can be obtained in nanoemulsions by 
increasing the percentage of the oil phase, but such disper 
sions require the use of large amounts of surfactants (7]. SLN 
can be formulated at high lipid concentrations (up to 30% oil 
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phase) with reasonable surfactant concentrations as high 
stability is provided by the use of a solid matrix (8]. However, 
the drug compounds to be encapsulated are generally poorly 
soluble in the lipid matrix and can be expelled because of 
polymorphie transitions following lipid crystallization [9]. The 
development of NLC bas successfully decreased drug leakage 
during storage by the inclusion of liquid lipids in the solid 
matrix but this complicates the formulation process (2]. 
Organogels are an interesting family of gelled oil based 
materials with great potential in the pharmaceutical field and 
particularly for drug delivery (10 12]. Consequently, many 
studies have been reported in the literature, but the majority 
of them describe the use of organogels as matrix implants or 
more recently coated microparticles for drug delivery (13 16]. 
Dispersions of organogel in aqueous solution of stabiliz 
ing agent have led to a new type of semi solid colloidal 
dispersion, halfway between nanoemulsions and SLN. Prep 
aration of the so called organogel nanoparticles is solvent 
free, with a simple hot dispersion and homogenization 
procedure using an ultrasound probe or Ultraturrax® tech 
nique (17 19]. In previous studies, we developed organogel 
dispersions based on 12 hydroxystearic acid (HSA), a well 
known low molecular weight organic gelator (LMOG) corn 
monly used in cosmetic formulations (17, 18]. HSA bas shown 
an efficient gelling capacity over a broad variety of oils, 
including vegetable oils. We demonstrated an enhanced
stability from organogel nanoparticles compared to emulsions
(0% HSA) as well as their capacity to encapsulate a lipophilic
compound [20, 21]. Furthermore, high drug loading can be
obtained with stable dispersions of up to 23% vol. of oil
phase, which make organogel nanoparticles a promising
vehicle for lipophilic compounds [17]. To date, only a very
few studies have been conducted on the use of organogel
based dispersion as vehicle of lipophilic compounds, and
there is still no clear evidence of the release behavior of such
systems [20 24].
The aim of this study was to evaluate HSA organogel
nanoparticles as a drug delivery system by conducting
stability studies and assessing their release proﬁle by in vitro
release experiments.
In the ﬁrst step, the inﬂuence of the proportions of stabilizing
agent (polyvinyl alcohol) and organogel dispersed on the size and
stability was investigated, in order to select the optimal formulation
in view of the encapsulation studies. We prepared organogel
nanoparticles based on castor oil and loaded with one of two
lipophilic drug models indomethacin (INDO) or ketoconazole
(KCZ). These two compounds are commonly used as models for
in vitro dissolution studies as they show distinct ionization behavior
and pH dependent solubility. They also present thermal stability
compatible with the preparation process of the gelled particles
(Table I). In addition, INDO and KCZ have already been studied
in other lipid nanoparticulate systems and have shown promising
results for several pharmaceutical applications, such as skin or oral
delivery [25 27].
MATERIALS AND METHODS
Materials
Indomethacin (INDO, 99% p), Ketoconazole (KCZ,
99% p), castor oil and 80% hydrolysed polyvinyl alcohol
(PVA, 98% p, Mn = 8000 10,000 g/mol) were purchased from
Sigma Aldrich (USA). 12 Hydroxystearic acid (HSA, 85% p)
was obtained from Alfa Aesar Gmbh (Germany). Ultrapure
water was used to prepare the dispersions. All other reagents
were of analytical grade.
Preparation Of Gelled Oil Nanoparticles
Gelled oil nanoparticles were prepared according to the
protocol described by Kirilov et al. [17], with some modiﬁca
tions. Preparation was based on the hot dispersion of an
organogel, forming emulsion droplets that led to organogel
nanoparticles after cooling. Castor oil was used to prepare the
organogels according to preliminary solubility assays showing
the best results for INDO and KCZ. Organogels were
prepared by adding HSA a low molecular weight organic
gelator to castor oil. The mixtures were placed in an oven
and heated at 90°C until complete dissolution of the HSA,
then cooled at room temperature to form a compact,
translucent gel. Organogels loaded with INDO or KCZ were
prepared by initially dissolving 3% (w/w) of the drug in castor
oil. Unloaded organogels (blanks) were also prepared.
A solution of PVA was used as a non ionic stabilizing
agent for the dispersion of the organogel. The mixture was
heated to 90°C in an oven for 1 h until the organogel melted,
leading to an oily layer at the surface of the solution. The hot
mixture was immediately emulsiﬁed by sonication (Vibracell,
Bioblock Scientiﬁc with a titanium probe, 20 kHz, 600 W) for
10 min. Cooling at room temperature then led to a colloidal
dispersion of organogel nanoparticles.
Particle Size, Polydispersity Index, And Zeta Potential
Analysis
The particle size and dispersity (Đ) of the dispersions were
assessed by dynamic light scattering (DLS) on a Malvern
Instruments (Ireland) Nano ZS with a He Ne Laser (633 nm) at
a scattering angle of 173° and at 25 ± 1°C. Themean hydrodynamic
diameter was calculated using the software provided by Malvern
Instruments, applying the Contin model to obtain data. Zeta
potential measurements were made on the same apparatus by
means of an electrophoretic light scattering technique at 25 ± 1°C.
Both measurements were made on diluted samples (5 mg of
dispersion in 3 mL of distilled water) of INDO, KCZ, and Blank
dispersions.
Differential Scanning Calorimetry Of Organogels
The inﬂuence of drug loading on the gelation properties
of organogels was assessed by differential scanning calorim
etry (Mettler Toledo, Viroﬂay, France) experiments. Castor
oil organogels were prepared (Blank, INDO, KCZ), then 5
20 mg samples were placed in hermetically sealed aluminum
pans. DSC runs were carried out with two heating cooling
cycles between 10 and 90°C at a constant rate of 3°C per
minute, and with an empty aluminum pan used as reference.
The sol gel transition temperatures (Tgel) and gel sol transi
tion temperatures (Tmelt) were determined on thermograms
with the STARe software provided by Mettler Toledo, and
using onset temperatures. (n = 4).
Quantification Of Drug Content In Organogel Nanoparticles
The INDO and KCZ contents of organogel nanoparticles
were determined in two steps. The total drug content was
determined by dissolving an accurately weighed aliquot of
organogel nanoparticles dispersion (100 mg) in 10 mL of
methanol, followed by UPLC analysis. Then, the non
incorporated fraction of the drug, or aqueous drug content,
was determined after separation of the aqueous phase by
ultracentrifugation/ultraﬁltration (Microcon Ultracel YM 100,
Millipore, Ireland). The clear ultraﬁltrate obtained was
diluted with methanol (1/10) before UPLC analysis. Encap
sulation efﬁciency (EE) was ﬁnally calculated as follows:
EE %ð Þ ¼ Total drug content gð Þ free drug content gð Þ
Total drug content gð Þ
 100
ð1Þ
Formulation Selection and Stability Measurements
The formulation of organogel dispersions intended for
the encapsulation study was selected in two steps. First, a
study was conducted on blank castor oil organogels in order
to determine the right HSA percentage to obtain gelled oil
particles of sufﬁcient strength and stability. Series of castor oil
organogels (n = 3) were prepared at the following HSA
concentrations: 4, 5, 7, 10, 12, 15, 20, and 25% (w/w), and
subjected to DSC analysis. Transition temperatures (Tgel and
Tmelt) were calculated on DSC thermograms using onset
temperatures and were then represented on a phase diagram.
Once the HSA organogel concentration was ﬁxed, two series
of blank organogel dispersions were prepared with various
PVA amounts: 0.5, 1, 2, 5% (w/w) and different proportions
of phase of organogel dispersed: 5, 10, 20, 30% (w/w). The
stability of the dispersions, kept in sealed glass bottles at 4°C,
was assessed over a period of 28 days with combined DLS
measurement and macroscopic observations scheduled at
different times: initial time, 1, 7, and 28 days. Formulations
were judged stable if no changes in particle size and no visual
destabilization creaming, phase separation, or presence of
compact aggregates were observed. Proportions of PVA
and gelled oil phase (OG) that gave dispersions of small size
and excellent stability were selected.
The stability of the organogel nanoparticles loaded with
INDO or KCZ was assessed by determining drug encapsula
tion and particle size over a period of 3 months. This was
performed on three different batches of each formulation,
which were kept in sealed glass bottles at 4°C.
Morphological Study
The morphology of castor oil organogel nanoparticles
was determined by transmission electron microscopy (TEM)
(JEOL JEM 1200EX, 70 kV). Diluted samples (5 mg of
dispersion in 5 mL of ultrapure water) were deposited on
copper grids and negatively stained with a sodium phospho
tungstate solution (1%, pH 7).
Drug Release Experiments
The drug release proﬁle of the dispersions was charac
terized by equilibrium dialysis in triplicate. Dialysis bags
(MWCO membrane, 6000 8000 Da, Spectrum Labs) were
ﬁlled with 15 mL of fresh organogel dispersions, then
suspended in 600 mL of release medium under 300 rpm
magnetic rotation at 37°C. At scheduled intervals, 1 mL of
release medium was collected for UPLC analysis, a constant
volume of release medium being maintained by addition of
fresh buffer. Drug concentration at each interval was
converted to release percentage by considering the initial
concentration of drug in the formulation, also determined by
UPLC.
Dialysis with KCZ organogel nanoparticles was carried
out with release media of various pH, with extreme values
corresponding to gastric (NaCl 0.05 M, HCl pH 1.2) and
Table I. Physicochemical characteristics of ketoconazole and indomethacin
a
Determined by saturation method. An excess amount of drug was stirred for 24h 
at 37°C, followed by syringe filtration (0.45 µm) and UPLC analysis.
b,c 
(28,29)
d,e (30,31)
Ketoconazole Indomethacin
Ionization behaviour Dibasic Weak acid
Solubility in water 
(pH 6.8) a 5 µg/mL 565 µg/mL
pKa b,c 6.5 and 2.9 4.5
LogP b,c 3.8 4 3.4 4.3
Thermal stabilityd,e >105°C >200°C
aDetermined by saturation method. An excess amount of drug was stirred for 24 h at 37°C, followed by syringe ﬁltration (0.45 μm) and UPLC
analysis
b,c [28, 29]
d,e [30, 31]
intestinal conditions (Phosphate buffer 0.1 M, pH 6.8).
Intermediate buffers of pH 4, pH 5, and pH 6 were also
prepared with different volume ratios of acetic acid/sodium
acetate 0.1 M solutions. Formulations in the dialysis bag were
previously diluted with the corresponding buffer medium to a
drug concentration of 0.1 mg/mL.
Dialysis with INDO organogel nanoparticles was carried
out with pH 6.8 buffer. The dialysis experiment was
performed on control groups in the same conditions with
either INDO dissolved in buffer medium at 0.1 mg/mL or
INDO dispersed as a suspension in the buffer medium at
1.0 mg/mL. For this part, drug concentration at each interval
was converted into release rate, corresponding to the amount
of drug released per unit of time.
In complement to the dialysis study, a simple release
study was performed by diluting INDO organogel nanopar
ticles in pH 6.8 buffer at a volume ratio of 1:5 or 1:50, and
stored either at 4 or 37°C for 48 h. The proportion of INDO
released was determined by assay of the aqueous phase
separated by centrifugation ﬁltration. The release was also
studied on non diluted samples in similar experimental
conditions.
Ultra Performance Liquid Chromatography Analysis
Samples from dialysis and encapsulation experiments
were analyzed by UPLC using a WATERS Acquity H Class
system combined with a UV detector. Separation was
performed through an Acquity UPLC BEM C18 (1.7 μm;
2.1 × 50 mm) column maintained at 40°C. Quantiﬁcation of
KCZ used a mobile phase of acetonitrile:ammonium acetate
10 mM (60:40), with a ﬂow rate of 1 mL/min and UV
detection at 220 nm, while INDO was quantiﬁed with a
mobile phase of acetonitrile:formic acid 0.1% (60:40), with a
ﬂow rate of 1 mL/min and UV detection at 265 nm.
Calibration curves were established with external solutions
(from 10 7 to 10 4 M) of INDO and KCZ in acetonitrile.
RESULTS AND DISCUSSION
Optimal Formulation Selection
Firstly, it was necessary to determine the most suitable
composition of the basic ingredients of the formulation. The
main ingredients were the organogelator (HSA), the castor
oil, and the water containing the stabilizing agent (PVA). The
amount of HSA was the ﬁrst parameter conditioning the
gelation temperature and the hardness of the organogel. A
DSC study investigated the inﬂuence of HSA concentration
on sol gel transition temperatures (Tgel) and gel sol transi
tion temperatures (Tmelt) of the organogel (Fig. 1). Hysteresis
was seen between Tgel and Tmelt. The hysteresis diminished
continuously as more HSA was added and was thus consid
ered to be linked to the strength of the organogel. However,
stability problems had been observed previously with an
excess of organogelator [21]. Then, the formulation with 15%
w/w of HSA was selected as it showed appropriate mechan
ical strength with Tgel and Tmelt above 37°C (physiological
temperature).
We then investigated the inﬂuence of the amount of
organogel dispersed and the PVA percentage on the mean
diameter of the particles (Fig. 2a). As expected, the particle
size variation of the dispersions was strongly correlated to the
amount of stabilizing agent used [32]. Indeed, at high
organogel content, the concentration of PVA was not
sufﬁcient to stabilize smaller droplets and a reduction in
particle size was observed when more PVA was added in the
dispersant phase. Interestingly, as shown in Fig. 2b, it was
possible to correlate directly the size of the dispersions to
PVA/OG ratio regardless of organogel content. For instance,
three different dispersions formulated at the same PVA/OG
phase ratio of 0.1 showed similar size dispersion of 400 nm.
Dispersions tended to reach a limit in terms of particle size
when high amounts of stabilizing agent (PVA) were used.
This is probably inherent to the dispersion method by
sonication which does not provide enough energy to produce
smaller particles [33]. A ratio of 0.2 appeared to be an
optimal ratio to provide good stability and limit the addition
of surfactant. Stabilities of the dispersions assessed by visual/
macroscopic observations combined with DLS measurements
are summed up in Table II. Dispersion stability was directly
correlated to the proportions of PVA employed. Stable
formulations (no creaming or aggregates before 1 month)
were achieved with PVA/OG phase ratios equal to at least
0.1. On the other hand, formulations with ratios below 0.05
could not lead to stable dispersions. Considering all these
results, we selected a formulation with 10% OG dispersion in
2% PVA. This formulation should provide small sized
organogel nanoparticles of excellent stability and limit the
use of stabilizing agent.
Influence Of Drug Loading On Gel Formation
DSC experiments were carried out in order to provide
information about the thermal properties of the organogel and
the inﬂuence of the two loaded drugs (3% w/w). This study was
done with organogels and not dispersions as previous inves
tigation by rheology had shown similar sol gel transitions
between organogels and organogel dispersions [17].
The inﬂuence of drug on gel formation was assessed, as
plotted on Fig. 3, which shows DSC heating and cooling
thermograms of unloaded, INDO loaded, and KCZ loaded
organogels. During cooling, onset temperatures correspond
ing to sol gel transitions (Tgel) were 55.8 (±1.8), 52.1 (±1.2)
Fig. 1. Sol gel and gel sol transition temperatures of HSA
organogels
and 54.4°C (±0.6) for unloaded, INDO and KCZ organogels,
respectively. Thus, drug loading did not interfere with the
gelation process to any great extent.
A small interference was also observed during heating,
with gel sol transition temperatures (Tmelt) of 45.0 (±3.8),
39.8 (±2.0), and 41.4°C (±1.3) for unloaded, INDO and KCZ
organogels, respectively.
When heating and cooling transitions were compared,
signiﬁcant hysteresis was observed between Tgel and Tmelt for
each organogel. In a previous study, similar DSC experiments
with soybean oil organogels loaded (0.06% w/w) with a highly
lipophilic compound, chloroaluminium phthalocyanine
(ClAlPc), had shown that the gelation process was affected
by drug loading [21]. Nevertheless, in the present study,
limited gelling alteration was observed with KCZ or INDO,
despite higher drug loading (3% w/w). This could be
explained either by the entrapment of less hydrophobic
compounds or by the use of a large amount of gelator in
our formulations.
Stability Of Gelled Oil Nanoparticles
The characteristics of gelled oil nanoparticles over a
storage period of 3 months at 4°C are shown in Table III. The
mean diameter of the gelled oil nanoparticles did not seem to
be inﬂuenced by drug loading, with values stable between 250
and 300 nm, and drug loading did not affect the size
distribution according to Đ measurements. In addition, the
stability of the organogel nanoparticles diluted in pH 1.2 and
pH 6.8 buffers was assessed by DLS, and no changes in
particle size were observed for at least 48 h. Zeta potential
measurements showed similar negative surface charge for all
formulations, due to the ionization of the carboxylic functions
of the HSA present at the surface of the particles.
EE were determined to highlight possible drug leakage
occurring during storage. Both INDO and KCZ organogel
nanoparticles showed good drug entrapment results (Table III).
EE was stable for a period of 1 month, with no signiﬁcant drug
leakage during this storage period. The small proportion of free
drug in the water phase of the dispersion was probably due to
initial leakage occurring during the hot dispersion phase of the
organogel.
However, extending the stability test to a longer period
(>3 months) revealed a slight decrease in EE for INDO
organogel nanoparticles, pointing to possible drug leakage
over longer periods. EE remained unchanged for KCZ
organogel nanoparticles. This may be explained by the better
Fig. 2. a Mean diameter of the particles obtained by DLS from 5, 10, 20, and 30% organogel dispersions according to the PVA percentage. b
Mean diameter of the particles according to the PVA (%)/OG dispersed (%) ratio
Table II. Stability by visual assessment (no creaming or aggregates)
at °C of organogel nanoparticles according to organogel dispersed
phase (%) and PVA (%)
PVA
0.5% 1% 2% 5%
Organogel phase 5% ≥28 days ≥28 days ≥28 days ≥28 days
10% <28 days ≥28 days ≥28 days ≥28 days
20% Unstable <28 days ≥28 days ≥28 days
30% Unstable <7 days <28 days ≥28 days Fig. 3. DSC thermograms examples of unloaded and drug loaded
(3% w/w) HSA (15% w/w) organogels
aqueous solubility of indomethacin leading to higher
partitioning in the water phase. Thus, drug partitioning may
be prevented by adjusting the pH of the dispersions. For
instance, formulations of indomethacin in submicron emul
sion or SLN were adjusted to pH 4 in order to favour the
localization of the drug in the oil phase, thus leading to better
entrapment efﬁciency [34, 35].
Morphological Study
The morphology and size of castor oil organogel nanopar
ticles were observed by TEM (Fig. 4). The images show
spherical particles with diameters in accordance with the DLS
measurements. We also observed that there is no differences
(size and morphology), before and after drug encapsulation.
Drug Release Profiles Of Organogel Nanoparticles
Figure 5a shows the release proﬁles of KCZ organogel
nanoparticles in release media of various pH. It was observed
that KCZ release increased when the pH of the release
medium was lowered, in accordance with the solubility proﬁle
of KCZ at different pH. KCZ solubility increased dramati
cally under acidic conditions because of the basicity of the
molecule and its protonation. Consequently, the release of
KCZ from organogel nanoparticles depends strongly on its
solubility in the release medium.
Figure 5b compares the release proﬁle of KCZ organogel
nanoparticles with INDO organogel nanoparticles and re
veals differences. Although INDO and KCZ have similar
lipophilicity (LogP values in Table I), they exhibit strongly
contrasting ionization behavior, leading to different solubility
proﬁles. For instance, the solubility of INDO at pH 6.8 is a
hundred times that of KCZ. As a result of these observations,
we can conclude that organogel nanoparticle release is mostly
dependent on drug partitioning with the external medium.
Further dialysis experiments were done exclusively
under Bsink conditions,^ otherwise the release would have
been dependent on the test conditions and would not describe
the properties of the delivery system [36]. Free drug was used
as the Bcontrol^ in order to investigate the release from
organogel nanoparticles. The experiments were done with
INDO, at two different concentrations that framed the
solubility limit of the compound in pH 6.8 buffer, used as
the release medium.
At 0.1 mg/mL, release from organogel nanoparticles was
compared to that from a solution, as plotted in Fig. 6a.
Identical release rates were observed, signifying the immedi
ate release of drug from organogel nanoparticles. In contrast
to these observations, previous work on massive organogels
loaded with ibuprofen showed sustained release, implying
both diffusion and erosion mechanisms [14]. Incidentally, in
this previous study, organogels with a larger amount of HSA
presented lower erosion rates and low diffusion, leading to
slower release rates. With organogel nanoparticles, the large
Table III. Stability assessment of gelled oil nanoparticles, 4°C (n 3), pH 7
Mean diameter (nm) Đ ξ Potential (mV) Encapsulation efﬁciency (%)
1 day Blank 259 (±12) 0.32 (±0.05) −34.7 (±5.8)
INDO 269 (±23) 0.31 (±0.12) −36.7 (±6.7) 99.0 (±0.1)
KCZ 282 (±28) 0.30 (±0.03) −31.2 (±6.3) 98.4 (±0.1)
1 month Blank 263 (±11) 0.23 (±0.02) −37.8 (±6.7)
INDO 271 (±20) 0.28 (±0.07) −32.4 (±5.8) 98.0 (±0.1)
KCZ 267 (±15) 0.25 (±0.03) −31.1 (±5.5) 97.4 (±0.1)
3 months Blank 250 (±19) 0.23 (±0.03) −37.2 (±6.6)
INDO 244 (±13) 0.26 (±0.05) −30.0 (±5.6) 91.9 (±0.2)
KCZ 266 (±16) 0.25 (±0.03) −25.9 (±4.7) 97.4 (±0.1)
Fig. 4. TEM micrograph of castor oil organogel nanoparticles, general view (a) and a
detail (b)
surface area of the dispersion implied a huge increase in the
diffusion, which enabled rapid release of the compound. In
consequence, we observed that release from organogel
nanoparticles depended only on the diffusion mechanism.
When the concentration was increased to 1.0 mg/mL, the
free drug Bcontrol^ went beyond the solubility limit of INDO
and became a saturated solution. As shown in Fig. 6b, release
rates were higher for organogel nanoparticles during the ﬁrst
3 h of the dialysis experiment and then became similar to
those of free drug for the rest of the study. This rapid release
can be explained by the enhanced solubility of INDO in the
oily vehicle, with the entrapped drug being solubilized and
readily available from diffusion. Thus, gelled oil nanoparticles
should exhibit a faster release proﬁle than SLN, in which the
encapsulated drug is generally in the solid state [9].
In addition to the dialysis experiments, release studies were
done by diluting INDO organogel nanoparticles in pH 6.8
buffer. As shown in Fig. 7, non diluted samples gave drug
release of 1.3 and 1.4% at 4 and 37°C, respectively, indicating
that temperature was of no major importance for drug release
during storage. Moreover, the amounts of free drug were in
accordance with the encapsulation in Table III. A massive
release of INDO was observed after dilution of the dispersions.
Higher dilutions led to higher leakage, as about 50% of INDO
was leaked after a 1:5 dilution, but the percentage was near
100% after 1:50 dilution. This is a conﬁrmation of the dialysis
experiments, in which near 100% release was obtained after
24 h under similar dilution conditions. Thus, these results
conﬁrm that the release mechanism from organogel nanoparti
cles is mostly governed by diffusion, with a partitioning of the
drug strongly correlated to its solubility and to the concentration
gradient in the aqueous phase.
Taking the example of the oral route, better bioavail
ability would be expected as dissolution is often a rate
limiting step for absorption [37, 38].
CONCLUSION
Organogel nanoparticles form an interesting family of
colloidal nanoparticles based on gelled oil. Past experiments
had already illustrated their potential use for drug encapsula
tion, with enhanced stability compared to emulsions and high
drug loading potency. In this study, we prepared castor oil
organogel nanoparticles loaded with KCZ or INDO, two
lipophilic compounds with distinct ionization behaviors. Drug
loading showed no impact on the particle size and stability of the
dispersions and did not much hinder the gelling process
according to DLS and DSC experiments. Encapsulation efﬁ
Fig. 5. a Release proﬁles of KCZ loaded organogel nanoparticles at 37°C according to release medium: pH 1.2 (white circle), pH 4 (black
diamond suit), pH 5 (increment), pH 6 (multiplication sign), pH 6.8 (black square). b Release proﬁles in pH 6.8 release medium of organogel
nanoparticles loaded with INDO (lozenge) or KCZ (black square)
Fig. 6. Release rate of INDO loaded organogel nanoparticles at 37°C (white circle) vs pure drug (black diamond suit) in pH 6.8 release medium
buffer, at initial drug concentrations of 0.1 mg/mL (a) and 1 mg/mL (b)
ciency was very satisfactory for both compounds, with stability
results suggesting very limited drug leakage occurring during
storage. The small amount of initial drug leakage had probably
happened during the dispersion step. In addition, EE results at
3 months suggest possible drug partitioning that would be
correlated with the solubility of the drug in the aqueous phase.
Release proﬁles determined by in vitro dialysis suggested an
immediate release of the drug from the organogel nanoparticles.
It seems that the solubilization of the drug enabled its rapid
diffusion out of the vehicle. Thus, the gel network of HSA ﬁbres
would not hinder the drug release. Also, the increased solubility
of the drug in the oil phasemay lead to a better bioavailability, as
more drug is readily available for diffusion. This ﬁrst evaluation
of organogel nanoparticles as vehicles for drug delivery has
conﬁrmed their potential in the pharmaceutical domain. Even
though no sustained release was enabled, the immobilization of
the oil in a gelled matrix was probably responsible for the
improved stability of the dispersions and the limited escape of
the drug during storage. These systems may constitute a
proﬁtable alternative to nanoemulsions or SLN for the delivery
of lipophilic compounds with regards to biocompatibility,
stability or scale up. Moreover, the adhesiveness of the lipid
based nanoparticle, which has been proved to facilitate the drug
tissue permeation, brings out the speciﬁc interest of organogel
nanoparticles in the ﬁeld of oral delivery.
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